Abstract:Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial agents, while effective against F. nucleatum infections, can exacerbate dysbiosis. This necessitates the discovery of more targeted narrow-spectrum antimicrobial agents. We therefore investigated the potential for the fusobacterial enoyl-ACP reductase II (ENR II) isoenzyme FnFabK (C4N14_ 04250) as a narrow-spectrum drug target. ENRs catalyze the rate-limiting step in the bacterial fatty acid synthesis pathway. Bioinformatics revealed that of the four distinct bacterial ENR isoforms, F. nucleatum specifically encodes FnFabK. Genetic studies revealed that fabK was indispensable for F. nucleatum growth, as the gene could not be deleted, and silencing of its mRNA inhibited growth under the test conditions. Remarkably, exogenous fatty acids failed to rescue growth inhibition caused by the silencing of fabK. Screening of synthetic phenylimidazole analogues of a known FabK inhibitor identified an inhibitor (i.e., 681) of FnFabK enzymatic activity and F. nucleatum growth, with an IC50 of 2.1 μM (1.0 μg/mL) and a MIC of 0.4 μg/mL, respectively. Exogenous fatty acids did not attenuate the activity of 681 against F. nucleatum. Furthermore, FnFabK was confirmed as the intracellular target of 681 based on the overexpression of FnFabK shifting MICs and 681-resistant mutants having amino acid substitutions in FnFabK or mutations in other genetic loci affecting fatty acid biosynthesis. 681 had minimal activity against a range of commensal flora, and it was less active against streptococci in physiologic fatty acids. Taken together, FnFabK is an essential enzyme that is amenable to drug targeting for the discovery and development of narrow-spectrum antimicrobial agents.

Enoyl Acyl Carrier Protein Reductase Inhibitors: A Patent Review (2006-2010)

Farnesoid X receptor modulators 2014-present: a patent review

Development of Mycobacterium tuberculosis Enoyl Acyl Reductase (InhA) Inhibitors: A Mini-Review

Navigating the Chemical Space of ENR Inhibitors: A Comprehensive Analysis

Tyrosyl-tRNA synthetase inhibitors: a patent review

Recent Advances in Inhibitors of Bacterial Fatty Acid Synthesis Type II (FASII) System Enzymes As Potential Antibacterial Agents.

RND-type Drug Eﬄux Pumps from Gram-negative Bacteria: Molecular Mechanism and Inhibition

Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target

Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria

Advances in the Synthesis and Biological Applications of Enoxacin-Based Compounds

Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps

Recent Progresses on Enediyne Antibiotics and their Targeted Drugs

Recent Progress in the Development of Small Molecule Nrf2 Activators: a Patent Review (2017-Present)

Discovery and Development of Novel Rhodanine Derivatives Targeting Enoyl-Acyl Carrier Protein Reductase.

Recent Advances in Enzyme Inhibition: A Pharmacological Review

Novel FabH inhibitors: a patent and article literature review (2000--2012).

Evaluation of a Series of 2-Napthamide Derivatives As Inhibitors of the Drug Efflux Pump AcrB for the Reversal of Antimicrobial Resistance

Design, Synthesis and Biological Activity Evaluation of Novel 4-Subtituted 2-Naphthamide Derivatives As AcrB Inhibitors

Ectonucleotidase inhibitors: an updated patent review (2017–2023)

Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria

Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 - 2010): a patent review.